No Data
No Data
Debang Securities: The pharmacy sector is oversold and has entered the bottom area. Bullish on varieties with high medical insurance proportion and competitive export enterprises.
Debon Securities is bullish on two main themes: varieties that increase their share in total medical insurance expenditures, and globally competitive enterprises in the export chain. The sub-areas include innovative drugs, traditional Chinese medicines, active pharmaceutical ingredients, and some medical instruments.
6-K: Report of foreign private issuer (related to financial reporting)
Hutchmed (China) (00013.HK) plans to hold a board of directors meeting on July 31 to approve its mid-term performance.
Hutchmed (China) (00013.HK) announced on June 26th that the company will hold a board meeting on Wednesday, July 31st, 2024 to approve the mid-term performance of the company and its subsidiaries for the six months ending on June 30th, 2024 (including) and release it at 7:00 pm that day (Hong Kong time).
Goldman Sachs Maintains Hutchmed (China)(HCM.US) With Hold Rating
Goldman Sachs analyst Paul Choi maintains $Hutchmed (China)(HCM.US)$ with a hold rating.According to TipRanks data, the analyst has a success rate of 48.0% and a total average return of 4.5% over the
GF Sec: Rated Hutchmed (China) as a "buy", with a target price of HKD 41.16.
GF Securities expects Hutchmed (China) to have a net income attributable to shareholders of -$116 million, $100 million, and $116 million for the years 2024-2026, respectively.
Hutchmed (China) (00013) will introduce the latest research and development progress on July 9th.
Hutchmed (China) Limited announced today in a statement that it will launch in 2024...